Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.53 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106908 | 0.83 | CYSLTR1 (0.46) | CYSLTR1ALOX5APGPBAR1CYSLTR2 | |
| SCHEMBL5106205 | 0.82 | CYSLTR1 (0.54) | CYSLTR1ALOX5APGPBAR1CYSLTR2 | |
| SCHEMBL5110623 | 0.81 | CYSLTR1 (0.53) | CYSLTR1ALOX5APGPBAR1CYSLTR2 | |
| SCHEMBL5110602 | 0.81 | GPBAR1 (0.48) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL5109781 | 0.74 | CYSLTR1 (0.42) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL5120823 | 0.73 | GPBAR1 (0.50) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL5377034 | 0.73 | CYSLTR1 (0.58) | CYSLTR1ALOX5APGPBAR1 | |
| SCHEMBL5112999 | 0.73 | CYSLTR1 (0.58) | CYSLTR1ALOX5APGPBAR1 | |
| SCHEMBL8801078 | 0.72 | CYSLTR1 (0.64) | CYSLTR1ALOX5APGPBAR1CYSLTR2 | |
| SCHEMBL5112459 | 0.72 | LMNA (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | CYSLTR1 806/4885ALOX5AP 2368/4885GPBAR1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.